How do genetics clinic nurses explain BRCA testing to Spanish-speaking patients who feel fine and do not understand why they need a genetic test?

The central misunderstanding in BRCA pre-test counseling is the belief that a genetic test is something you do because you are already sick. The patient who feels fine, has no lump, has had a normal mammogram, and was referred only because a family member had cancer cannot understand the logic of testing when there is nothing wrong with her. What needs to be explained is that inherited cancer risk and active cancer are two different things, and that the entire value of genetic testing is finding out about risk before cancer develops, not after. BRCA1 and BRCA2 are genes that repair DNA damage in breast and ovarian tissue. When a person inherits a pathogenic variant in one of these genes, the repair function is reduced, and the cells in those tissues accumulate errors at a faster rate over time, which is why cancer risk is elevated. A BRCA1 carrier who has not yet developed cancer is not less at risk than one who has — she simply has not yet reached the point in the accumulation curve where cancer emerged. Testing identifies whether she is on that elevated-risk trajectory so that surveillance can be adjusted accordingly. The alternative — not testing — is not neutral. If she carries a variant and does not know it, she will continue with standard screening intervals that are designed for average-risk women, which means cancers that could have been caught earlier will not be caught earlier. “La prueba genética no es para saber si tiene cáncer ahora — eso ya lo saberíamos por la mamografía y el examen. Es para saber si tiene el tipo de riesgo heredado que aumenta la probabilidad de que el cáncer se desarrolle en el futuro. Si el resultado es positivo, eso cambia lo que hacemos de ahora en adelante: cómo la monitoreamos, con qué frecuencia, y qué opciones tiene para reducir el riesgo antes de que el cáncer aparezca. Si esperamos a que el cáncer aparezca para descubrirlo, perdemos exactamente la ventana que hace que el conocimiento sea valioso.” (The genetic test is not to find out if you have cancer right now — we would know that from the mammogram and the exam. It is to find out whether you have the type of inherited risk that increases the probability that cancer will develop in the future. If the result is positive, that changes what we do going forward: how we monitor you, how frequently, and what options you have to reduce risk before cancer appears. If we wait for cancer to appear to discover it, we lose exactly the window that makes the knowledge valuable.)

How do genetics clinic nurses explain prophylactic mastectomy and oophorectomy to Spanish-speaking BRCA1 carriers who feel healthy?

The patient who is told to consider removing healthy organs is confronting a recommendation that is unlike almost any other medical recommendation she has encountered. Usually surgery is proposed because something is wrong with the organ being removed. Risk-reducing surgery is proposed precisely because the organs are currently healthy — the goal is to prevent them from becoming diseased. This logic is counterintuitive and takes careful explanation. What the genetics clinic nurse needs to convey is the magnitude of the risk being managed. BRCA1 carriers face a lifetime breast cancer risk of 65–72% compared to approximately 12% in the general population. They face a lifetime ovarian cancer risk of 39–44% compared to approximately 1.3% in the general population. Prophylactic bilateral mastectomy reduces breast cancer risk by 90–95%. Prophylactic salpingo-oophorectomy reduces ovarian cancer risk by over 95% — and also reduces breast cancer risk by approximately 50% in premenopausal women, because it removes the ovarian estrogen that can promote hormone-receptor-positive breast cancer. The distinction the nurse must also convey is that ovarian cancer and breast cancer are not equivalent in terms of what screening can offer. Breast cancer has effective early detection: regular mammography, MRI, and clinical exam catch most breast cancers at a curable stage. Ovarian cancer has no equivalent screening test — CA-125 and transvaginal ultrasound, used as surveillance for high-risk women, have not been shown to reduce ovarian cancer mortality in large trials. For BRCA1 carriers, the only strategy with documented survival benefit for ovarian cancer is risk-reducing salpingo-oophorectomy, not surveillance. “Para el cáncer de mama tenemos herramientas para detectarlo temprano — la mamografía, la resonancia, los exámenes. Si aparece cáncer en la vigilancia intensiva, lo encontramos en una etapa en que es muy tratable. Para el cáncer de ovario no tenemos una prueba de detección temprana con el mismo nivel de eficacia. El cáncer de ovario con frecuencia no produce síntomas hasta que ya está avanzado. Por eso la cirugía profiláctica del ovario es diferente a la del seno — no es que sea la única opción para ambos, sino que para el ovario es la única opción que ha demostrado cambiar la supervivencia.” (For breast cancer we have tools to detect it early — mammography, MRI, exams. If cancer appears during intensive surveillance, we find it at a stage where it is very treatable. For ovarian cancer we do not have an early detection test with the same level of effectiveness. Ovarian cancer frequently produces no symptoms until it is already advanced. That is why prophylactic ovarian surgery is different from breast surgery — it is not that surgery is the only option for both, but that for the ovary it is the only option that has been shown to change survival.)

How do genetics clinic nurses explain the Lynch syndrome colonoscopy interval to Spanish-speaking patients who think the polyp removal took care of the problem?

The most common source of confusion for newly diagnosed Lynch syndrome patients about surveillance is the belief that a polyp that has been removed is a problem that has been solved. The next colonoscopy in one to two years feels unnecessary — what would it find, if the polyp that was there was already removed? The genetics clinic nurse needs to explain two distinct concepts: first, that removing a polyp prevents that specific polyp from progressing to cancer but does not change the underlying process that produces polyps in the Lynch colon; and second, that the Lynch colon forms polyps faster than the average-risk colon, which is precisely why the surveillance interval is compressed. Lynch syndrome is caused by a germline pathogenic variant in one of the mismatch repair genes — MLH1, MSH2, MSH6, or PMS2. These genes produce proteins that proofread DNA replication, catching and correcting errors before they accumulate. When one of these genes carries a pathogenic variant, the proofreading function is reduced. Cells with replication errors that would normally be corrected instead accumulate those errors, and over time this accelerated error accumulation drives polyp formation and, eventually, cancer. The standard colonoscopy interval for average-risk adults is ten years because the average-risk colon takes approximately ten years to progress from a new adenoma to cancer. Lynch syndrome colons progress on a compressed timeline — estimates from Lynch surveillance registries suggest a 2–3 year window from new adenoma to potential cancer in some Lynch subtypes. This is why the interval is one to two years rather than ten. “El problema no es el pólipo que se extrajo — ese ya no es un riesgo. El problema es que el síndrome de Lynch hace que su colon forme pólipos nuevos más rápido que el de una persona sin el síndrome. Para la mayoría de las personas, un pólipo tarda diez años en convertirse en un problema. Para usted, ese proceso puede pasar más rápido. Por eso la colonoscopía cada uno a dos años no es para buscar el pólipo que sacó — es para encontrar los nuevos antes de que tengan tiempo de progresar.” (The problem is not the polyp that was removed — that one is no longer a risk. The problem is that Lynch syndrome makes your colon form new polyps faster than a person without the syndrome. For most people, a polyp takes ten years to become a problem. For you, that process can happen faster. That is why colonoscopy every one to two years is not to look for the polyp that was removed — it is to find the new ones before they have time to progress.)

What should genetics clinic nurses say in Spanish when a BRCA1 carrier asks whether she must have surgery or whether surveillance is an option instead?

Risk-reducing surgery is not a requirement for BRCA1 carriers, and genetics clinic nurses should make this explicit. The decision between intensive surveillance and risk-reducing surgery is one of the genuinely difficult decisions in hereditary cancer management, and it involves values, priorities, and circumstances that differ among patients. The nurse who presents it as a mandate rather than an option undermines the informed decision-making process that is the entire point of genetic counseling. What should be clear, however, is the difference in the level of risk reduction each path offers, and specifically the difference in options for breast versus ovarian cancer. For breast cancer: intensive surveillance (annual mammography beginning at age 25–29, with alternating MRI at the same frequency) identifies most cancers at early and treatable stages. Multiple studies of BRCA1 carriers under surveillance have shown that cancers detected in surveillance programs are caught at earlier stages than those found symptomatically. Risk-reducing mastectomy offers a 90–95% reduction in risk but is a major surgery with physical and psychological implications that patients weigh differently. For ovarian cancer: the surveillance options (CA-125 every six months, transvaginal ultrasound) have not been shown in randomized trials to reduce ovarian cancer mortality. The evidence for risk-reducing salpingo-oophorectomy reducing ovarian cancer mortality is strong; the evidence for surveillance reducing it is not. “Hay opciones, y ninguna es obligatoria. Para el cáncer de mama, la vigilancia intensiva es una alternativa real — los estudios muestran que la mayoría de los cánceres encontrados en programas de vigilancia en portadoras de BRCA1 se detectan en etapas tempranas y tratables. La cirugía da una protección mayor, pero muchas mujeres eligen la vigilancia y tienen resultados muy buenos. Para el cáncer de ovario la situación es diferente: las pruebas de vigilancia disponibles — el CA-125 y el ultrasonido — no han demostrado en estudios clínicos que reduzcan la mortalidad por cáncer de ovario. La cirugía profiláctica de ovario es la única opción con evidencia de beneficio en supervivencia. Eso no significa que deba hacerlo ahora — significa que necesitamos hablar sobre cuándo y en qué momento tiene sentido para usted.” (There are options, and none is mandatory. For breast cancer, intensive surveillance is a real alternative — studies show that most cancers found in surveillance programs in BRCA1 carriers are detected at early and treatable stages. Surgery provides greater protection, but many women choose surveillance and have very good outcomes. For ovarian cancer the situation is different: the available surveillance tests — CA-125 and ultrasound — have not been shown in clinical studies to reduce ovarian cancer mortality. Prophylactic ovarian surgery is the only option with evidence of survival benefit. That does not mean you must do it now — it means we need to talk about when and at what point it makes sense for you.)

What are the most important Spanish phrases for genetics clinic nurses working with Spanish-speaking patients with hereditary cancer syndromes?

Genetics clinic nursing involves three recurring communication failures that are specific to hereditary cancer: the patient who cannot understand why she needs a genetic test when she has no cancer (the pre-test counseling failure); the patient who receives a positive BRCA or Lynch result and cannot connect the abstract concept of increased lifetime risk to the concrete decisions being asked of her (the post-test counseling failure); and the patient who cannot understand why her surveillance schedule looks nothing like the standard schedule other people in her family or community follow. In each case the nurse who explains the mechanism — what BRCA genes do normally, what happens to cancer risk when one carries a pathogenic variant, why the colon of a Lynch syndrome patient forms polyps on a different timeline than the average-risk colon — is the person who prevents the most consequential errors: the patient who declines testing and misses the window for early intervention, the patient who has a positive result but cannot accept the implications because the biology was never explained, and the patient who misses surveillance appointments because the interval seemed excessive given that her last colonoscopy was normal. For pre-test counseling: “la prueba no es para saber si ya tiene cáncer — es para saber si tiene el tipo de riesgo que cambia lo que hacemos de ahora en adelante.” For post-test risk explanation: “este resultado no significa que va a tener cáncer con certeza — significa que su riesgo durante la vida es significativamente más alto que el promedio, y que eso cambia las decisiones sobre vigilancia y prevención que están disponibles para usted.” For Lynch syndrome surveillance: “no estamos buscando el pólipo que se sacó — estamos buscando los que su colon va a formar de nuevo, porque el síndrome de Lynch hace que eso pase más rápido que en una persona sin el síndrome.” (For pre-test counseling: “the test is not to find out if you already have cancer — it is to find out if you have the type of risk that changes what we do going forward.” For post-test risk explanation: “this result does not mean you will certainly get cancer — it means your lifetime risk is significantly higher than average, and that changes the surveillance and prevention decisions that are available to you.” For Lynch syndrome surveillance: “we are not looking for the polyp that was removed — we are looking for the ones your colon will form again, because Lynch syndrome makes that happen faster than in a person without the syndrome.”)

July 22, 2026 · Clinical Spanish · Genetics · Hereditary Cancer · Oncology Nursing

Spanish for genetics clinic nurses — the patient referred for BRCA testing who cannot understand why she needs a test for a disease she does not have, the patient whose BRCA1 carrier status has been confirmed and who cannot understand why healthy organs are being discussed for removal, and the patient with Lynch syndrome who cannot understand why she needs colonoscopy every one to two years when her polyp was just removed

Carmen Medina is 47. She is a hotel housekeeper from Los Angeles. Six months ago, her younger sister — 44 years old, healthy, no symptoms — was diagnosed with invasive breast cancer. The diagnosis came at a routine mammogram. Her sister went through surgery and is now in chemotherapy. The oncologist, reviewing the family history, noted that Carmen and her sister’s mother died of ovarian cancer at age 63, that a maternal aunt had breast cancer at 58, and that the pattern was consistent with possible hereditary breast and ovarian cancer syndrome. Carmen’s sister underwent genetic testing. The result: a BRCA1 pathogenic variant.

Her sister called Carmen three weeks ago and told her what the genetic counselor said: Carmen should get tested. She has a 50% chance of having inherited the same variant.

Carmen came in today for her pre-test genetic counseling appointment. She is sitting across from the genetics clinic nurse with her arms folded.

— No entiendo por qué necesito esta prueba. Yo no tengo cáncer. Me siento perfectamente bien. ¿Para qué sirve un examen de algo que todavía no ha pasado?

I do not understand why I need this test. I do not have cancer. I feel perfectly fine. What is the point of a test for something that has not happened yet?

What this post covers

This post covers three conversations that recur in genetics clinic nursing when the patient speaks Spanish. The first is Carmen’s — the patient referred for BRCA testing after a first-degree relative’s hereditary cancer diagnosis, who is entirely asymptomatic and cannot understand why a genetic test is relevant to her when she feels fine, has no lump, and has never been told anything was wrong. The second is Marisela Gutiérrez, 39, a teacher from San Jose who received her BRCA1 pathogenic variant result three weeks ago and is now being counseled about risk-reducing surgery options — prophylactic bilateral mastectomy and salpingo-oophorectomy — by her genetic counselor and gynecologic oncologist. Marisela feels completely healthy. She has two children. She is 39. She cannot understand why she would have surgery to remove organs that are currently working fine. The third is Rosa Vargas, 52, a cleaning service worker from Houston who had her first colonoscopy at 50 after her mother’s colorectal cancer at 55. A polyp was found, removed, and sent to pathology. The biopsy showed mismatch repair protein deficiency. Follow-up germline testing confirmed Lynch syndrome — an MLH1 pathogenic variant. Rosa has now been told she needs colonoscopy every one to two years for the rest of her life. She cannot understand why: the polyp that was found was removed. Wasn’t that the problem? Why does she need another scope so soon if the last one came back negative for cancer?

Each of these three patients arrived at the genetics clinic with a gap between what the medicine is recommending and what makes sense to them from their own experience and logic. Carmen’s logic is that tests are for sick people, and she is not sick. Marisela’s logic is that surgery is for damaged organs, and her organs are not damaged. Rosa’s logic is that a polyp that was removed was a problem that was solved. In each case, the genetics clinic nurse who explains the mechanism — what BRCA genes do, what inherited cancer risk means before cancer develops, why prophylactic surgery and surveillance differ in their evidence base, why the Lynch colon forms polyps on a different timeline than the average-risk colon — is the person who makes the clinical plan coherent rather than arbitrary.

Scenario one: Carmen and the genetic test for something that has not happened yet

Genetics clinic nurse Lucía Reyes introduced herself when she came into the room. She noticed the folded arms. She has seen this before — not resistance exactly, more a kind of suspended judgment. Carmen drove forty minutes to be here. She came because her sister asked her to. But she has not yet been persuaded that this appointment concerns her.

Lucía: — Carmen, antes de hablar sobre la prueba, quiero hacerle una pregunta. Usted mencionó que se siente perfectamente bien. ¿Esto quiere decir que prefiere no saber, o que todavía no estoy convenciéndola de que el resultado le sería útil?

Carmen, before we talk about the test, I want to ask you a question. You mentioned that you feel perfectly fine. Does that mean you prefer not to know, or that I have not yet convinced you that the result would be useful to you?

Carmen: — Lo segundo. No entiendo cómo un resultado de un gen me va a decir algo útil si todavía no hay nada malo.

The second. I do not understand how a gene result is going to tell me something useful if there is still nothing wrong.

Lucía: — Es una pregunta lógica, y tiene razón en hacerla. Permita que le explique por qué el resultado de esta prueba sería distinto de la mayoría de los resultados que usted ha tenido en su vida — porque tiene razón que la mayoría de las pruebas médicas le dicen si algo ya está pasando. Esta es diferente. Lo que le voy a contar hoy cambió completamente cómo lo entendí yo la primera vez que me lo explicaron, así que escucheme un momento.

That is a logical question, and you are right to ask it. Allow me to explain why the result of this test would be different from most results you have had in your life — because you are right that most medical tests tell you whether something is already happening. This one is different. What I am going to tell you today completely changed how I understood it the first time someone explained it to me, so listen to me for a moment.

What BRCA genes do and what happens when one carries a pathogenic variant

Lucía: — Todos tenemos genes BRCA1 y BRCA2. Son genes cuya función normal es reparar el ADN. Las células del cuerpo se dividen constantemente — las del seno, del ovario, de cualquier tejido. Cada vez que una célula se divide, copia su ADN. Ese proceso de copia no es perfecto. Comete errores. La función del gen BRCA1 es detectar esos errores y repararlos antes de que se acumulen. Cuando eso funciona bien, los errores se corrigen. Cuando hay una variante patógena en el gen BRCA1, esa función de reparación está reducida. Los errores en el ADN se acumulan más rápido. Y con el tiempo, esa acumulación de errores en las células del seno o del ovario puede llevar al desarrollo de cáncer.

We all have BRCA1 and BRCA2 genes. They are genes whose normal function is to repair DNA. The cells of the body divide constantly — breast cells, ovarian cells, cells of any tissue. Every time a cell divides, it copies its DNA. That copying process is not perfect. It makes errors. The function of the BRCA1 gene is to detect those errors and repair them before they accumulate. When that works well, the errors are corrected. When there is a pathogenic variant in the BRCA1 gene, that repair function is reduced. Errors in the DNA accumulate faster. And over time, that accumulation of errors in breast or ovarian cells can lead to the development of cancer.

Carmen: — ¿Pero yo no he tenido ningún síntoma.

But I have not had any symptoms.

Lucía: — Exactamente. Eso es lo más importante que quiero que entienda hoy. Una variante en BRCA1 no produce síntomas. No duele. No se nota. Una mujer puede tener la variante toda su vida y sentirse completamente bien hasta el día en que el cáncer se desarrolla. Sentirse bien no es evidencia de que la variante no esté ahí. Es exactamente lo que se espera antes de que el cáncer aparezca.

Exactly. That is the most important thing I want you to understand today. A variant in BRCA1 does not produce symptoms. It does not hurt. It is not noticeable. A woman can carry the variant her entire life and feel completely well until the day cancer develops. Feeling well is not evidence that the variant is not there. It is exactly what is expected before cancer appears.

Carmen is quiet. She unfolds her arms slightly.

Carmen: — Entonces, ¿en qué cambia algo el resultado? Si tengo la variante, no significa que voy a tener cáncer con seguridad. Mi hermana tiene la variante y muchas mujeres con la variante no desarrollan cáncer.

So what does the result change? If I have the variant, it does not mean I will definitely get cancer. My sister has the variant and many women with the variant do not develop cancer.

Why knowing versus not knowing is not a neutral choice

Lucía: — Tiene razón en que no es una certeza. Una mujer con la variante BRCA1 tiene un riesgo de cáncer de mama a lo largo de la vida de aproximadamente 65 a 72 por ciento. El riesgo de la población general es 12 por ciento. Eso es una diferencia muy grande — no es una garantia, pero es un riesgo que cambia significativamente las probabilidades. Y el punto de saber no es que el cáncer sea inevitable. El punto es que saber cambia lo que podemos hacer.

You are right that it is not a certainty. A woman with the BRCA1 variant has a lifetime breast cancer risk of approximately 65 to 72 percent. The general population risk is 12 percent. That is a very large difference — it is not a guarantee, but it is a risk that changes the odds significantly. And the point of knowing is not that cancer is inevitable. The point is that knowing changes what we can do.

Carmen: — ¿Qué cambia?

What changes?

Lucía: — Para una mujer con riesgo promedio, la mamografía anual empieza a los 40 años. Para una portadora de BRCA1, la vigilancia empieza a los 25 años — con mamografía y resonancia magnética alternadas cada seis meses. La resonancia detecta tumores que la mamografía puede perder, especialmente en tejido mamario denso. Usted tiene 47 años. Si tiene la variante, eso significa que ha tenido 22 años de riesgo elevado con vigilancia de riesgo promedio. No podemos recuperar esos años. Pero lo que sí podemos hacer desde hoy, si el resultado es positivo, es cambiar el protocolo — y también hablar sobre las opciones de reducción de riesgo que existen. Si el resultado es negativo, usted sale de aquí sabiendo que no heredó la variante que tiene su hermana, y puede continuar con la vigilancia estándar. No saber el resultado no es estar en el medio — no saber el resultado es seguir como si el riesgo elevado no pudiera estar ahí, cuando en realidad puede estarlo.

For a woman of average risk, annual mammography begins at 40. For a BRCA1 carrier, surveillance begins at 25 — with alternating mammography and MRI every six months. MRI detects tumors that mammography can miss, especially in dense breast tissue. You are 47. If you have the variant, that means you have had 22 years of elevated risk with average-risk surveillance. We cannot recover those years. But what we can do starting today, if the result is positive, is change the protocol — and also discuss the risk-reduction options that exist. If the result is negative, you leave here knowing you did not inherit the variant your sister has, and you can continue with standard surveillance. Not knowing the result is not being in the middle — not knowing the result is continuing as if the elevated risk could not be there, when in fact it could be.

Carmen looks at her hands for a moment.

Carmen: — ¿Y si es positivo, qué pasa después?

And if it is positive, what happens next?

Lucía: — Eso es exactamente lo que veremos en la próxima cita, si el resultado es positivo. Pero lo que sí le puedo decir ahora mismo es que existe un plan. No es “tiene la variante, lo siento mucho.” Es: tiene la variante, y esto es lo que hacemos con esa información para mantenerla bien. La prueba en sí misma es solo una muestra de sangre o saliva. ¿Quiere que procedamos?

That is exactly what we will look at at the next appointment, if the result is positive. But what I can tell you right now is that there is a plan. It is not “you have the variant, I am sorry.” It is: you have the variant, and this is what we do with that information to keep you well. The test itself is just a blood or saliva sample. Would you like us to proceed?

Carmen: — Sí. Si mi hermana pudo hacerlo, yo también.

Yes. If my sister could do it, so can I.

Scenario two: Marisela and the surgery for organs that are not sick

Marisela Gutiérrez is 39. She is a fifth-grade teacher from San Jose. She is married, has two children aged nine and twelve, and runs a reading group at her school on Friday afternoons. Three weeks ago she received a call from the genetic counselor: her BRCA1 pathogenic variant result came back positive. The phone call lasted forty-five minutes. Since then she has barely slept.

Today she is meeting with genetics clinic nurse Elena Torres for a post-result counseling visit before her upcoming appointment with the gynecologic oncologist. Marisela has been reading. She has read about prophylactic bilateral mastectomy. She has read about salpingo-oophorectomy. She came in with a printed stack of pages from three websites and a notebook with questions she wrote down at midnight when she could not sleep.

Marisela: — Me siento completamente bien. Mis senos están bien. Mi última mamografía fue normal. Mis ovarios están bien — mi ginecóloga me hace exámenes todos los años y todo ha sido normal. ¿Cómo voy a considerar operarme partes del cuerpo que no tienen nada malo?

I feel completely well. My breasts are fine. My last mammogram was normal. My ovaries are fine — my gynecologist examines me every year and everything has been normal. How am I supposed to consider having surgery on parts of the body that have nothing wrong with them?

Elena: — Es la pregunta más importante que podemos hablar hoy, y quiero que la trabajemos despacio porque la respuesta tiene dos partes muy diferentes — una para el seno y otra para el ovario — y la lógica detrás de cada una es distinta. ¿Está de acuerdo en que empecemos por ahí?

That is the most important question we can discuss today, and I want us to work through it slowly because the answer has two very different parts — one for the breast and one for the ovary — and the logic behind each is different. Do you agree we start there?

Breast cancer risk in BRCA1 carriers and what surveillance can offer

Elena: — Para el cáncer de mama, primero hablemos del riesgo. Una mujer sin la variante BRCA1 tiene un riesgo de cáncer de mama a lo largo de la vida de aproximadamente 12 por ciento. Usted, con la variante BRCA1, tiene un riesgo de aproximadamente 65 a 72 por ciento. Eso no significa que el cáncer sea seguro — significa que la probabilidad es significativamente más alta. Pero para el cáncer de mama, tenemos herramientas de detección temprana que son realmente efectivas en portadoras de BRCA1.

For breast cancer, let us start with the risk. A woman without the BRCA1 variant has a lifetime breast cancer risk of approximately 12 percent. You, with the BRCA1 variant, have a risk of approximately 65 to 72 percent. That does not mean cancer is certain — it means the probability is significantly higher. But for breast cancer, we have early detection tools that are genuinely effective in BRCA1 carriers.

Marisela: — Me dijeron que necesito empezar resonancias. ¿Por qué resonancias si tengo mamografías cada año?

They told me I need to start MRIs. Why MRIs if I have mammograms every year?

Elena: — La mamografía y la resonancia magnética detectan cosas diferentes en tejido mamario. La mamografía es muy buena para detectar calcificaciones — pequeños depósitos de calcio que a veces son una señal temprana de cáncer. La resonancia es mejor para detectar masa tumoral en tejido mamario denso, que es el tipo de tejido que muchas mujeres jóvenes tienen y que en la mamografía aparece blanco, igual que el tumor. En portadoras de BRCA1, especialmente las menores de 50 años, la resonancia detecta tumores que la mamografía pierde — y detectarlos antes significa que generalmente se encuentran en etapas muy tempranas donde el tratamiento es más efectivo. El protocolo de vigilancia intensiva para BRCA1 — mamografía y resonancia alternadas cada seis meses a partir de los 25 años — ha mostrado en estudios de seguimiento a largo plazo que la mayoría de los cánceres detectados en portadoras bajo ese protocolo se encuentran en etapas I o II, que son las etapas más tratables.

Mammography and MRI detect different things in breast tissue. Mammography is very good at detecting calcifications — small calcium deposits that are sometimes an early sign of cancer. MRI is better at detecting tumor mass in dense breast tissue, which is the type of tissue many younger women have and which on mammography appears white, the same as a tumor. In BRCA1 carriers, especially those under 50, MRI detects tumors that mammography misses — and detecting them earlier means they are generally found at very early stages where treatment is most effective. The intensive surveillance protocol for BRCA1 — alternating mammography and MRI every six months beginning at age 25 — has shown in long-term follow-up studies that most cancers detected in carriers under that protocol are found at stage I or II, which are the most treatable stages.

Marisela: — Entonces, ¿la vigilancia funciona para el seno?

So surveillance works for the breast?

Elena: — Sí. La cirugía profiláctica reduce el riesgo más — un 90 a 95 por ciento — pero muchas portadoras de BRCA1 eligen la vigilancia intensiva y tienen resultados muy buenos. La decisión entre las dos opciones depende de muchos factores que son personales — cómo vive con la incertidumbre, la importancia que le da al riesgo residual, su historia familiar. No hay una respuesta correcta universal para el seno. Las dos opciones tienen evidencia. La vigilancia no es rendirse — es una elección activa con un protocolo riguroso que funciona. Cuando lleguemos a la conversación sobre la cirugía del seno, vamos a tener tiempo para trabajar eso. Pero primero quiero hablarle del ovario, porque ahí la situación es diferente.

Yes. Prophylactic surgery reduces the risk more — 90 to 95 percent — but many BRCA1 carriers choose intensive surveillance and have very good outcomes. The decision between the two options depends on many personal factors — how you live with uncertainty, the importance you place on residual risk, your family history. There is no universal right answer for the breast. Both options have evidence. Surveillance is not giving up — it is an active choice with a rigorous protocol that works. When we get to the conversation about breast surgery, we will have time to work through that. But first I want to talk about the ovary, because there the situation is different.

Why ovarian cancer is different and why surveillance does not offer the same protection

Marisela: — ¿Por qué es diferente para el ovario?

Why is it different for the ovary?

Elena: — El cáncer de ovario en portadoras de BRCA1 tiene un riesgo a lo largo de la vida de aproximadamente 39 a 44 por ciento. En la población general ese riesgo es 1.3 por ciento. Eso es una diferencia muy grande. Ahora, la diferencia con el seno es la siguiente: para el cáncer de seno tenemos pruebas de detección temprana que funcionan. Para el cáncer de ovario, no tenemos el equivalente. El CA-125 — que es un marcador en la sangre — y el ultrasonido transvaginal se usan como vigilancia en mujeres de alto riesgo. Pero en los ensayos clínicos grandes — incluido el ensayo UKFOCSS y el ensayo GOG 199 — esa vigilancia no ha demostrado reducir la mortalidad por cáncer de ovario en portadoras de BRCA1. ¿Sabe por qué?

Ovarian cancer in BRCA1 carriers has a lifetime risk of approximately 39 to 44 percent. In the general population that risk is 1.3 percent. That is a very large difference. Now, the difference from the breast is this: for breast cancer we have early detection tests that work. For ovarian cancer, we do not have the equivalent. CA-125 — which is a blood marker — and transvaginal ultrasound are used as surveillance in high-risk women. But in the large clinical trials — including the UKFOCSS trial and the GOG 199 trial — that surveillance has not been shown to reduce ovarian cancer mortality in BRCA1 carriers. Do you know why?

Marisela: — No.

No.

Elena: — Porque el cáncer de ovario, en muchos casos, pasa de etapa I a etapa III en un período muy corto — a veces entre una vigilancia y otra. No hay síntomas en las etapas tempranas. Cuando los síntomas aparecen — la distención abdominal, la saciedad rápida, la molestia pélvica — con frecuencia el cáncer ya está avanzado. Y el cáncer de ovario en etapa III tiene una supervivencia a cinco años de aproximadamente 29 por ciento. Comparado con etapa I, donde la supervivencia a cinco años es superior al 92 por ciento. El problema es que no hay una prueba de detección que capture consistentemente el cáncer de ovario en etapa I antes de que produzca síntomas. Para portadoras de BRCA1, la cirugía profiláctica de ovario — la salpingo-ooforectomía — reduce el riesgo de cáncer de ovario en más del 95 por ciento. Es la única estrategia para la que existe evidencia de reducción de mortalidad en portadoras de BRCA1.

Because ovarian cancer, in many cases, goes from stage I to stage III in a very short period — sometimes between one surveillance visit and the next. There are no symptoms in the early stages. When symptoms appear — abdominal distension, early satiety, pelvic discomfort — the cancer is frequently already advanced. And ovarian cancer at stage III has a five-year survival of approximately 29 percent. Compared to stage I, where five-year survival exceeds 92 percent. The problem is that there is no detection test that consistently captures ovarian cancer at stage I before it produces symptoms. For BRCA1 carriers, prophylactic ovarian surgery — salpingo-oophorectomy — reduces ovarian cancer risk by more than 95 percent. It is the only strategy for which there is evidence of mortality reduction in BRCA1 carriers.

Marisela is very still.

Marisela: — ¿Entonces no hay forma de vigilar el ovario que funcione realmente?

So there is no way to monitor the ovary that actually works?

Elena: — No de la misma manera que el seno. Lo que tenemos funciona mal comparado con lo que necesitamos. Eso no significa que deba operarse mñana, ni que sea una decisión fácil. La cirugía implica menopausia quirúrgica si se hace antes de los 51 años, y eso tiene implicaciones que hay que manejar — síntomas, salud ósea, algunos efectos cognitivos. Pero la razón por la que el ginecólogo oncológico quiere tener esta conversación con usted no es para presionarla — es para darle el tiempo de entender la situación antes de llegar a esa cita. ¿Tiene preguntas sobre lo que acabó de escuchar?

Not in the same way as the breast. What we have works poorly compared to what we need. That does not mean you must have surgery tomorrow, nor that it is an easy decision. Surgery implies surgical menopause if done before age 51, and that has implications that need to be managed — symptoms, bone health, some cognitive effects. But the reason the gynecologic oncologist wants to have this conversation with you is not to pressure you — it is to give you the time to understand the situation before that appointment. Do you have questions about what you just heard?

Marisela: — Tengo muchas preguntas. Pero creo que por primera vez entiendo por qué me lo están pidiendo.

I have many questions. But I think for the first time I understand why they are asking it of me.

How prophylactic oophorectomy also reduces breast cancer risk

Elena: — Hay un último punto sobre la cirugía de ovario que vale la pena mencionar porque puede cambiar cómo piensa sobre la relación entre las dos decisiones. La ooforectomía profiláctica antes de la menopausia natural no solo reduce el riesgo de cáncer de ovario. En portadoras de BRCA1 premenopáusicas, eliminar los ovarios también reduce el riesgo de cáncer de mama en aproximadamente 50 por ciento. Eso es porque el estrógeno que producen los ovarios puede promover el crecimiento de ciertos tipos de céncer de mama. Cuando los ovarios se retiran antes de la menopausia, esa fuente de estrógeno desaparece. Eso no hace que la decisión sea más simple — la menopausia quirúrgica tiene su propio conjunto de efectos que manejar — pero significa que cuando el ginecólogo oncológico le hable de cronología — cuándo hacerlo, qué edad es óptima — parte de esa conversación será sobre cómo la decisión del ovario afecta al riesgo del seno también.

There is one last point about ovarian surgery that is worth mentioning because it may change how you think about the relationship between the two decisions. Prophylactic oophorectomy before natural menopause does not only reduce ovarian cancer risk. In premenopausal BRCA1 carriers, removing the ovaries also reduces breast cancer risk by approximately 50 percent. That is because the estrogen the ovaries produce can promote the growth of certain types of breast cancer. When the ovaries are removed before menopause, that source of estrogen disappears. That does not make the decision simpler — surgical menopause has its own set of effects to manage — but it means that when the gynecologic oncologist talks to you about timing — when to do it, what age is optimal — part of that conversation will be about how the ovarian decision also affects breast risk.

Marisela writes something in her notebook. She underlines it twice.

Marisela: — Voy a la cita con el ginecólogo con preguntas, no con miedo. Eso es diferente.

I will go to the gynecologist appointment with questions, not with fear. That is different.

Scenario three: Rosa and the colonoscopy for the polyp she already removed

Rosa Vargas is 52. She is a cleaning service worker from Houston. She started her own business twelve years ago — four employees, commercial contracts with three office buildings and a medical clinic. She has been healthy her whole life. Her mother was diagnosed with colorectal cancer at 55 and died at 61. That history was what sent Rosa to her gastroenterologist at age 50 for her first colonoscopy.

The colonoscopy found a 6mm polyp in the sigmoid colon. It was removed. The pathology result said it was a tubular adenoma with normal architecture. Routine, the gastroenterologist told her. But the immunohistochemistry staining showed that the polyp was missing a protein called MLH1 — mismatch repair deficiency. The gastroenterologist referred her to the genetics clinic.

Germline testing confirmed it: Rosa has an MLH1 pathogenic variant. Lynch syndrome.

She has been told she needs colonoscopy every one to two years. She has also been told she needs to discuss gynecologic surveillance with her gynecologist, because Lynch syndrome also increases uterine and ovarian cancer risk. She came in today with a single question that she wrote on a piece of paper and placed on the table between her and genetics clinic nurse Carmen Fuentes.

The paper says: “¿Por qué necesito colonoscopía cada año si ya me sacaron el pólipo?”

Why do I need colonoscopy every year if they already removed my polyp?

Carmen: — Esta es exactamente la pregunta correcta, y la respuesta tiene que ver con cómo el síndrome de Lynch afecta al colon. ¿Puedo explicarle cómo funciona normalmente el colon y qué cambia cuando hay una variante en un gen de reparación?

That is exactly the right question, and the answer has to do with how Lynch syndrome affects the colon. Can I explain to you how the colon normally works and what changes when there is a variant in a repair gene?

What mismatch repair genes do and why Lynch syndrome accelerates polyp formation

Carmen: — Las células del colon se dividen constantemente para renovar el revestimiento del intestino. Cada vez que una célula se divide, copia su ADN. Ese proceso comete errores. Tenemos genes cuya función específica es revisar esas copias y corregir los errores antes de que la célula se divida de nuevo. Usted tiene una variante en el gen MLH1 — que es uno de esos genes correctores. Cuando el corrector no funciona bien, los errores en el ADN de las células del colon se acumulan más rápido de lo normal. Esa acumulación más rápida es lo que hace que las personas con síndrome de Lynch formen pólipos con más frecuencia y en más cantidad que la población general.

The cells of the colon divide constantly to renew the intestinal lining. Every time a cell divides, it copies its DNA. That process makes errors. We have genes whose specific function is to review those copies and correct the errors before the cell divides again. You have a variant in the MLH1 gene — which is one of those corrector genes. When the corrector does not work well, errors in the DNA of colon cells accumulate faster than normal. That faster accumulation is what causes people with Lynch syndrome to form polyps more frequently and in larger numbers than the general population.

Rosa: — ¿Y el pólipo que me sacaron?

And the polyp they removed?

Carmen: — Sacar ese pólipo fue exactamente lo correcto. Ese pólipo específico ya no es un riesgo. Pero — y esto es lo importante — sacarlo no cambió el proceso que lo produjo. Su colon todavía tiene la variante de MLH1. La función de corrección todavía está reducida. Su colon todavía forma pólipos más rápido que el de una persona sin el síndrome. Sacar el pólipo es como sacar una hoja caída del techo de un cuarto que tiene una gotera. La hoja ya no está — pero el techo sigue teniendo la gotera, y van a seguir cayendo más hojas.

Removing that polyp was exactly the right thing to do. That specific polyp is no longer a risk. But — and this is the important part — removing it did not change the process that produced it. Your colon still has the MLH1 variant. The correction function is still reduced. Your colon still forms polyps faster than that of a person without the syndrome. Removing the polyp is like removing a fallen leaf from the ceiling of a room that has a roof leak. The leaf is no longer there — but the roof still has the leak, and more leaves will keep falling.

Rosa picks up her piece of paper from the table and turns it over.

Rosa: — Entonces la colonoscopía cada año es para encontrar los pólipos nuevos.

So the colonoscopy every year is to find the new polyps.

Carmen: — Exactamente. Y hay una razón específica por la que el intervalo es tan corto. Para la mayoría de las personas sin el síndrome de Lynch, un adenoma tarda aproximadamente diez años en progresar a cáncer. Por eso la colonoscopía estándar en la población general es cada diez años después de una colonoscopía negativa. En el síndrome de Lynch, ese intervalo está comprimido. Los registros de seguimiento de pacientes con Lynch muestran que algunos pólipos pueden progresar en dos a tres años. Con un intervalo de cinco años, algunos cánceres llegarían antes de la próxima colonoscopía. El intervalo de uno a dos años está calibrado para ese ritmo específico.

Exactly. And there is a specific reason the interval is so short. For most people without Lynch syndrome, an adenoma takes approximately ten years to progress to cancer. That is why standard colonoscopy in the general population is every ten years after a negative scope. In Lynch syndrome, that interval is compressed. Follow-up registries of Lynch patients show that some polyps can progress in two to three years. With a five-year interval, some cancers would arrive before the next colonoscopy. The one-to-two-year interval is calibrated to that specific rhythm.

Why Rosa’s mother’s colorectal cancer matters for how Lynch syndrome works in her family

Rosa: — Mi mamá murió de cáncer de colon y nunca le hicieron colonoscopía. ¿Significa que ella también tenía el síndrome de Lynch?

My mother died of colon cancer and she never had a colonoscopy. Does that mean she also had Lynch syndrome?

Carmen: — Es muy probable. El síndrome de Lynch es hereditario — se hereda de un padre o una madre. Si usted tiene la variante MLH1, una de dos cosas es cierta: o la heredó de su mamá o la heredó de su papá. Dado que su mamá tuvo cáncer de colon a los 55 — una edad relativamente temprana, y el colon es uno de los cánceres más asociados con el síndrome de Lynch — es muy probable que la variante viniera de ella. Eso no se puede confirmar sin la prueba genética de su mamá, que ya no es posible. Pero lo que sí se puede hacer es informar a sus hijos y hermanos, porque cada uno de ellos tiene un 50 por ciento de probabilidad de haber heredado la misma variante. La buena noticia — y realmente es buena noticia — es que su mamá probablemente no murió por falta de un medicamento. Murió porque no se sabía que tenía el síndrome y no tuvo la vigilancia que lo habría detectado a tiempo. Usted tiene lo que ella no tuvo: el diagnóstico. Eso cambia todo.

It is very likely. Lynch syndrome is hereditary — inherited from one parent or the other. If you have the MLH1 variant, one of two things is true: you inherited it from your mother or from your father. Given that your mother had colon cancer at 55 — a relatively early age, and the colon is one of the cancers most associated with Lynch syndrome — it is very likely the variant came from her. That cannot be confirmed without your mother’s genetic test, which is no longer possible. But what can be done is to inform your children and siblings, because each of them has a 50 percent probability of having inherited the same variant. The good news — and it really is good news — is that your mother probably did not die for lack of a medication. She died because it was not known she had the syndrome and she did not have the surveillance that would have detected it in time. You have what she did not have: the diagnosis. That changes everything.

Rosa is silent for a long moment.

Rosa: — Mi hija tiene 28 años. ¿Ella debería hacerse la prueba?

My daughter is 28. Should she get the test?

Carmen: — Sí. Y lo antes posible. Si tiene la variante, la vigilancia empieza a los 20 a 25 años en el síndrome de Lynch. Si tiene 28 y no sabe, ya tiene algunos años de riesgo elevado sin vigilancia. Podemos hablar hoy de cómo referirla.

Yes. And as soon as possible. If she has the variant, surveillance begins at age 20 to 25 in Lynch syndrome. If she is 28 and does not know, she already has some years of elevated risk without surveillance. We can talk today about how to refer her.

Rosa: — Llevo semanas pensando que el pólipo era el problema y que ya estaba resuelto. Ahora entiendo que el pólipo no era el problema — era la señal del problema.

I have spent weeks thinking the polyp was the problem and that it was already solved. Now I understand that the polyp was not the problem — it was the signal of the problem.

Carmen: — Eso es exactamente correcto. Y que lo haya entendido así es lo que va a hacer que usted no termine como su mamá.

That is exactly right. And understanding it that way is what is going to mean you do not end up like your mother.

What Lynch syndrome means for gynecologic cancer risk

Carmen: — Hay una parte más que quiero que sepamos hoy porque es algo que muchas pacientes con síndrome de Lynch no saben hasta que alguien se los explica. El síndrome de Lynch no solo aumenta el riesgo de cáncer colorrectal. También aumenta el riesgo de cáncer de endometrio — el revestimiento del útero. En mujeres con síndrome de Lynch, el riesgo de cáncer de endometrio durante la vida es de aproximadamente 40 a 60 por ciento, dependiendo del gen afectado. En la población general es aproximadamente 3 por ciento. Por eso el ginecólogo que la va a ver va a hablar sobre vigilancia ginecológica — biopsia endometrial anual y posiblemente ultrasonido transvaginal — a partir de los 30 a 35 años. Eso no es adicional a la colonoscopía como una complicación extra. Es parte del plan de vigilancia completo del síndrome de Lynch.

There is one more part I want us to cover today because it is something that many Lynch syndrome patients do not know until someone explains it to them. Lynch syndrome does not only increase colorectal cancer risk. It also increases the risk of endometrial cancer — the lining of the uterus. In women with Lynch syndrome, lifetime endometrial cancer risk is approximately 40 to 60 percent, depending on which gene is affected. In the general population it is approximately 3 percent. That is why the gynecologist who will see you will talk about gynecologic surveillance — annual endometrial biopsy and possibly transvaginal ultrasound — beginning at age 30 to 35. That is not additional to the colonoscopy as an extra complication. It is part of the complete Lynch syndrome surveillance plan.

Rosa: — ¿Hay algo más que el síndrome afecte?

Is there anything else the syndrome affects?

Carmen: — El síndrome de Lynch también se asocia con cáncer de ovario, de estómago, de vías urinarias, y de otras localizaciones, aunque esos riesgos son más bajos que el riesgo colorrectal y endometrial. La vigilancia estándar de Lynch se enfoca en el colon y el endometrio porque son donde el riesgo es más alto y donde la vigilancia tiene más evidencia de beneficio. Las otras localizaciones se pueden abordar por síntomas, no en general por vigilancia sistemática. Le voy a dar hoy un resumen escrito de todo lo que hemos cubierto para que no tenga que recordar todo esto de memoria. ¿Tiene preguntas sobre lo que acabamos de hablar?

Lynch syndrome is also associated with ovarian cancer, stomach cancer, urinary tract cancer, and other sites, although those risks are lower than the colorectal and endometrial risk. Standard Lynch surveillance focuses on the colon and endometrium because those are where the risk is highest and where surveillance has the most evidence of benefit. The other sites can be addressed by symptoms, not generally by systematic surveillance. I will give you a written summary today of everything we have covered so you do not have to remember all of this from memory. Do you have questions about what we just discussed?

Rosa: — Solo una. ¿Por qué nadie me explicó esto en la otra cita?

Just one. Why did nobody explain this to me at the other appointment?

Carmen: — Porque este tipo de explicación requiere tiempo, y la mayoría de los sistemas de salud no tienen ese tiempo incorporado. Por eso existe la enfermería de genética. Para que usted tenga esta conversación con alguien que no tiene que apurarse a la próxima paciente en cinco minutos.

Because this type of explanation requires time, and most healthcare systems do not have that time built in. That is why genetics nursing exists. So that you have this conversation with someone who does not have to rush to the next patient in five minutes.

Eight practical phrases for genetics clinic nurses

The conversations in this post center on a type of clinical communication that is uncommon in most healthcare encounters: explaining risk that has not yet become disease, and recommending action on organs that are currently healthy. The following phrases address the most common communication gaps in genetics clinic nursing for Spanish-speaking patients.

1. Explaining that genetic testing is not for diagnosing current disease

The patient who feels fine and does not understand why a genetic test applies to her needs a reframe of what genetic testing is for before the test itself makes sense.

Esta prueba no es para saber si tiene cáncer ahora — eso ya lo sabríamos por los exámenes clínicos. Es para saber si tiene el tipo de riesgo heredado que cambia lo que hacemos de ahora en adelante: con qué frecuencia la vigilamos, qué tipo de estudios hacemos, y qué opciones de reducción de riesgo tiene disponibles.

(This test is not to find out if you have cancer right now — we would already know that from the clinical exams. It is to find out whether you have the type of inherited risk that changes what we do going forward: how frequently we monitor you, what type of studies we do, and what risk-reduction options are available to you.)

2. Explaining why not knowing your BRCA status is not a neutral choice

The patient who prefers not to know needs to understand that the absence of information is itself a clinical risk, not a neutral middle position.

No saber el resultado no es estar en un punto neutral. Si tiene la variante y no lo sabe, seguimos con los protocolos de riesgo promedio. Si el cáncer se desarrolla, puede que lo encontremos más tarde de lo que lo habríamos encontrado con el protocolo de vigilancia intensiva. La decisión de no saber es en sí misma una decisión clínica con consecuencias que vale la pena entender.

(Not knowing the result is not being in a neutral position. If you have the variant and do not know it, we continue with average-risk protocols. If cancer develops, we may find it later than we would have found it with the intensive surveillance protocol. The decision not to know is itself a clinical decision with consequences that are worth understanding.)

3. Explaining why prophylactic surgery on healthy tissue is clinically rational

The patient who cannot understand surgery on healthy organs needs the risk magnitude explained before the surgical option makes sense.

La cirugía profiláctica no es para órganos que están enfermos. Es para órganos que tienen un riesgo muy alto de desarrollar enfermedad — y para los que la cirugía ha demostrado que reduce ese riesgo más de lo que puede hacerlo la vigilancia sola. El riesgo de cáncer de ovario en portadoras de BRCA1 durante la vida es de aproximadamente 40 por ciento. La vigilancia disponible no ha demostrado en ensayos clínicos que reduzca la mortalidad. La cirugía sí ha demostrado esa reducción. Por eso la conversación existe.

(Prophylactic surgery is not for organs that are diseased. It is for organs that have a very high risk of developing disease — and for which surgery has been shown to reduce that risk more than surveillance alone can. The lifetime ovarian cancer risk in BRCA1 carriers is approximately 40 percent. The available surveillance has not been shown in clinical trials to reduce mortality. Surgery has been shown to produce that reduction. That is why the conversation exists.)

4. Explaining the surveillance versus surgery distinction for breast and ovary

The BRCA1 carrier who thinks the options are identical for breast and ovary needs to understand that the evidence base is different for each.

Para el cáncer de mama, la vigilancia intensiva — mamografía y resonancia alternadas cada seis meses — tiene evidencia de que detecta los cánceres en etapas tempranas. La cirugía da más protección, pero muchas portadoras de BRCA1 bajo vigilancia tienen muy buenos resultados. Para el ovario, las pruebas de vigilancia disponibles no han demostrado en ensayos clínicos que reduzcan la mortalidad. La decisión no es la misma para los dos órganos porque la situación no es la misma.

(For breast cancer, intensive surveillance — alternating mammography and MRI every six months — has evidence that it detects cancers at early stages. Surgery provides more protection, but many BRCA1 carriers under surveillance have very good outcomes. For the ovary, the available surveillance tests have not been shown in clinical trials to reduce mortality. The decision is not the same for both organs because the situation is not the same.)

5. Explaining what the Lynch syndrome colon does that an average-risk colon does not

The Lynch syndrome patient who thinks removing her polyp solved the problem needs the mechanism explained before the surveillance interval makes sense.

El síndrome de Lynch no produce un pólipo — produce una condición en la que el colon forma pólipos más rápido que el de una persona sin el síndrome. Sacar el pólipo que encontramos fue exactamente lo correcto — ese pólipo ya no es un riesgo. Pero el colon todavía tiene la variante que hace que formen pólipos a ese ritmo. El próximo estudio no es para buscar ese pólipo — es para encontrar los nuevos antes de que tengan tiempo de progresar.

(Lynch syndrome does not produce a polyp — it produces a condition in which the colon forms polyps faster than that of a person without the syndrome. Removing the polyp we found was exactly the right thing to do — that polyp is no longer a risk. But the colon still has the variant that causes them to form at that rate. The next study is not to look for that polyp — it is to find the new ones before they have time to progress.)

6. Explaining why the Lynch syndrome colonoscopy interval is one to two years and not ten

The patient who knows the standard interval is ten years and cannot understand why hers is so different needs the timeline compressed.

El intervalo de diez años en la población general existe porque un adenoma normal tarda aproximadamente diez años en progresar a cáncer. En el síndrome de Lynch ese proceso está acelerado. Los registros de seguimiento muestran que algunos pólipos en pacientes con Lynch pueden progresar en dos a tres años. Con un intervalo de cinco años, algunos cánceres llegarían antes de la próxima colonoscopía. El intervalo de uno a dos años está calibrado para ese ritmo específico de su colon, no para el ritmo de la población general.

(The ten-year interval in the general population exists because a normal adenoma takes approximately ten years to progress to cancer. In Lynch syndrome that process is accelerated. Follow-up registries show that some polyps in Lynch patients can progress in two to three years. With a five-year interval, some cancers would arrive before the next colonoscopy. The one-to-two-year interval is calibrated to that specific rhythm of your colon, not to the rhythm of the general population.)

7. Explaining Lynch syndrome endometrial cancer risk to women who did not know

The Lynch syndrome patient who came in focused only on colon cancer needs to understand the gynecologic component before she can consent to the full surveillance plan.

El síndrome de Lynch no solo afecta al colon. En mujeres, el riesgo de cáncer de endometrio durante la vida es de aproximadamente 40 a 60 por ciento, dependiendo del gen afectado. En la población general ese riesgo es 3 por ciento. Por eso el plan de vigilancia completo para el síndrome de Lynch incluye la ginecología — biopsia endometrial anual a partir de los 30 a 35 años. El colon y el endometrio son las dos localizaciones donde el riesgo es más alto y donde la vigilancia tiene más evidencia.

(Lynch syndrome does not only affect the colon. In women, lifetime endometrial cancer risk is approximately 40 to 60 percent, depending on which gene is affected. In the general population that risk is 3 percent. That is why the complete Lynch syndrome surveillance plan includes gynecology — annual endometrial biopsy beginning at age 30 to 35. The colon and the endometrium are the two sites where the risk is highest and where surveillance has the most evidence.)

8. Explaining why family members should be tested and what it means for them

The patient who has received a positive result needs to understand the implications for her first-degree relatives and what the 50% inheritance probability means in practice.

Cada hijo o hermano suyo tiene un 50 por ciento de probabilidad de haber heredado la misma variante — no un 50 por ciento de probabilidad de tener cáncer, sino de tener el mismo tipo de riesgo elevado que usted. Si tienen la variante y no lo saben, pueden no estar recibiendo la vigilancia que corresponde a su riesgo real. Si se hacen la prueba y sale negativa, salen de aquí sabiendo que no heredaron la variante y pueden continuar con la vigilancia estándar. La prueba de un familiar suyo puede ser la diferencia entre detectar un cáncer temprano o encontrarlo tarde.

(Each child or sibling of yours has a 50 percent probability of having inherited the same variant — not a 50 percent probability of having cancer, but of having the same type of elevated risk as you. If they have the variant and do not know it, they may not be receiving the surveillance that corresponds to their actual risk. If they get tested and the result is negative, they leave here knowing they did not inherit the variant and can continue with standard surveillance. Testing a family member of yours may be the difference between detecting a cancer early or finding it late.)

Practice these conversations with ClinicaLingo

The three conversations in this post involve a type of clinical communication that almost never appears in standard Spanish-for-healthcare courses: explaining risk before disease, recommending action on currently healthy tissue, and navigating the gap between what a patient’s logic predicts and what the evidence shows. Carmen’s logic — that a test is for sick people and she is not sick — is reasonable for most medical contexts and wrong for this one. Marisela’s logic — that surgery is for diseased organs and her organs are not diseased — is similarly reasonable and similarly wrong in the specific context of BRCA1 ovarian cancer risk, where the absence of a reliable screening test makes surgery the only evidence-based option. Rosa’s logic — that a removed polyp is a solved problem — makes sense for most polyps in most colons and is wrong specifically because of how Lynch syndrome changes the rate at which her colon creates new ones. Getting these explanations right in Spanish — with the vocabulary and metaphors that make inherited risk legible, with the mechanism explanations that connect the abstract gene variant to the concrete clinical decision, with the tone that is honest about risk magnitudes without creating paralysis — takes practice. The ClinicaLingo practice scenarios cover genetics clinic conversations alongside oncology, emergency, and specialty nursing across the 155-scenario library. The 50-phrase PDF gives you the phrases that appear most often across the full library, organized by clinical situation. The full blog library covers every specialty from pediatric emergency nursing to correctional health nursing to transplant coordination.